Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Reports Strong Second Quarter 2025 Results and Business Updates
Summary
Regeneron Pharmaceuticals, Inc. reported a 4% increase in second quarter 2025 revenues to $3.68 billion. The company saw significant growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo, along with multiple regulatory approvals. Non-GAAP EPS increased 12% to $12.89. The company also announced important updates from its clinical pipeline, including FDA approvals for Lynozyfic and Dupixent in additional indications.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement